CN103519185A - 用于防治化学性肝损伤的保健品 - Google Patents
用于防治化学性肝损伤的保健品 Download PDFInfo
- Publication number
- CN103519185A CN103519185A CN201310535588.6A CN201310535588A CN103519185A CN 103519185 A CN103519185 A CN 103519185A CN 201310535588 A CN201310535588 A CN 201310535588A CN 103519185 A CN103519185 A CN 103519185A
- Authority
- CN
- China
- Prior art keywords
- preventing
- health care
- care product
- liver injury
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 15
- 206010067125 Liver injury Diseases 0.000 title abstract description 8
- 231100000753 hepatic injury Toxicity 0.000 title abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 230000006378 damage Effects 0.000 claims description 11
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 claims description 4
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 9
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 abstract 1
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 230000000091 immunopotentiator Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 1
- IXQKXEUSCPEQRD-NRNCYQGDSA-N (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C IXQKXEUSCPEQRD-NRNCYQGDSA-N 0.000 description 1
- BJWWOUUGCAPHOV-UHFFFAOYSA-N 1,3-dibenzylisoquinoline Chemical class C=1C2=CC=CC=C2C(CC=2C=CC=CC=2)=NC=1CC1=CC=CC=C1 BJWWOUUGCAPHOV-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- IHTCCHVMPGDDSL-ZJNDIJRCSA-N Cucurbitacin A Natural products O=C([C@@](O)(C)[C@H]1[C@@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(CO)[C@H]2CC=C2C(C)(C)C(=O)[C@H](O)C[C@@H]12)/C=C/C(OC(=O)C)(C)C IHTCCHVMPGDDSL-ZJNDIJRCSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- QZJJDOYZVRUEDY-UHFFFAOYSA-N Dihydrocucurbitacin B Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(=O)C1(C)C QZJJDOYZVRUEDY-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000704611 Fig cryptic virus Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000521581 Millettia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 241000304432 Sedum sarmentosum Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000003944 fast scan cyclic voltammetry Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008767 xiaochaihu Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于防治化学性肝损伤的保健品，该保健品是由五味子乙素、原花青素为主要原料制备而得，该保健品对化学性肝损伤有确切疗效。
Description
技术领域
本发明属于生物医药领域，具体涉及一种用于防治化学性肝损伤的保健品。
背景技术
在我国，因化学药物、病原体或过量饮酒等因素导致的肝病患者已逾千万，肝炎为严重威胁我国人民身体健康的主要疾患之一。肝炎是肝脏发生炎性病变的总称，在肝炎的临床治疗中，一般采用综合治疗法，即抗病毒药、免疫增强剂及保肝药配合治疗。抗病毒药、免疫增强剂着重于清除体内的病毒，保肝药着重于肝脏的恢复。目前真正有效的抗病毒药寥寥无几，如拉米呋啶、泛昔洛韦等抗乙肝病毒药物，也无法完全抑制病毒。目前公认的抗乙肝病毒有效的免疫增强剂为干扰素，也无法克服病毒的反跳问题。因此在病毒性肝炎的治疗中，抗病毒药、免疫增强剂及保肝药都十分重要，在化学毒物损伤性肝炎的治疗中尤其需要保肝药物，所以保肝药的市场巨大。
目前，国内外对中草药抗肝损伤的研究十分活跃，国内研究的有中草药单方、中草药复方和从中草药中提取的有效单体。
1.中草药单方
王要军等人研究发现冬虫夏草具有保护肝脏的作用，可以防止肝细胞点状坏死和局灶性坏死，抑制肝假小叶的形成。黄芪可以使大鼠肝纤维化程度明显降低，减少I、III、IV型胶原在肝内的沉积。丹参是一种很有前途的抗肝损伤中药，其作用机制是多方面的，如改善肝内微循环，抑制脂质过氧化，保护肝细胞，促进沉积的胶原降解和重吸收等。三七具有活血化淤的功效，能抑制肝内成纤维细胞的活性，减少胶原纤维的产生。此外，甘草、茯苓、五味子、柴胡、红花、垂盆草、水飞蓟等中药的抗肝损伤的作用在实验研究中也得到了证实。
2.中草药复方
除了经典的复方制剂，如小柴胡汤、桃红四物汤等外，结合中医理论，把有效单味中药合理组合，形成新的复方制剂，可提高抗肝损伤的效果。王宝恩等将丹参、黄芪、鸡血藤组成活血化淤方剂，可以明显防止CCl4所致肝纤维化和肝硬化的形成。由党参、黄芪、红枣组成的方剂有扶正补虚的功效，能减轻肝细胞变性坏死，抑制肝细胞纤维组织增生和假小叶的形成，对肝硬化有一定的防治作用。
3.中草药中提取的有效单体
较早研究的有齐墩果酸和葫芦素B通过保护肝细胞，降低刺激，间接抑制肝纤维化的启动和发展。甘草甜素能明显抑制肝硬化的形成。陈在忠等研究表明川芎嗪能明显降低大鼠血清谷丙转氨酶、丙二醛、III型前胶原及肝组织丙二醛的含量，提高肝组织中超氧化歧化酶的活性。汉防己甲素是从防己根块中提取的一种双苄基异喹啉类生物碱，其抗肝损伤的效果已经得到证实。氧化苦参碱是从植物山豆根中提取的一种生物碱，对慢性丙型肝炎有良好的治疗效果，体外培养细胞研究发现氧化苦参碱对大鼠肝Ito细胞增殖有抑制作用。
随着人民生活水平和生活方式的不断改变，各种中药护肝产品应运而生，但多数都存在效果不尽人意等缺点，至今未有令人十分满意的护肝产品。
发明内容
本发明的目的在于提供一种用于防治化学性肝损伤的保健品，该保健品对化学性肝损伤有辅助保护作用。
为达到上述目的，本发明的用于防治化学性肝损伤的保健品是由五味子乙素、原花青素为主要原料制备而得，五味子乙素和原花青素的最佳重量配比为1:15。
本发明的用于防治化学性肝损伤的保健品，在上述成分的基础的上，直接或者再加入适当的食用或药用辅料，可以制成胶囊剂、片剂、颗粒剂等各种剂型。上述可以加入的食用或药用辅料包括：稀释剂、助悬剂、崩解剂、抗氧化剂、乳化剂、黏合剂和防腐剂。
具体实施方式
实施例1：用于防治化学性肝损伤的保健品，其原料及重量份为：五味子乙素10份、原花青素150份，加入适量辅料，制成胶囊剂、片剂、颗粒剂等。
实施例2：对CCl4所致小鼠化学性肝损伤的保护作用
将受试小鼠随机分组，每组10只，连续给药7天，于末次给药后1小时皮下注射0.5%CCl4油溶剂0.1mg/kg进行急性肝损伤模型的复制，16小时后眼眶静脉丛采血，分离血清，测定血清中ALT、AST的含量。将给药各组指标与模型组作T-test检验。
表1.对CCl4所致小鼠化学性肝损伤的保护作用
与空白对照组比较，#p<0.05；与模型对照组比较，*p<0.05
试验表明，本发明给药组血清AST、ALT值明显低于模型对照组，并接近于空白对照组，表明本发明保健品对化学性肝损伤有辅助保护作用，且具有显效快、疗程短、成本低、副作用小等特点。
Claims (1)
1.用于防治化学性肝损伤的保健品，其特征为：它是由五味子乙素、原花青素为主要原料制备而得，五味子乙素和原花青素的最佳重量配比为1:15。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310535588.6A CN103519185A (zh) | 2013-11-02 | 2013-11-02 | 用于防治化学性肝损伤的保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310535588.6A CN103519185A (zh) | 2013-11-02 | 2013-11-02 | 用于防治化学性肝损伤的保健品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103519185A true CN103519185A (zh) | 2014-01-22 |
Family
ID=49921821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310535588.6A Pending CN103519185A (zh) | 2013-11-02 | 2013-11-02 | 用于防治化学性肝损伤的保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103519185A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784370A (zh) * | 2015-04-30 | 2015-07-22 | 陈大忠 | 一种能够清除自由基的抗氧化药物组合物及其制备方法 |
| CN104784371A (zh) * | 2015-04-30 | 2015-07-22 | 陈大忠 | 一种抗酒精性肝损伤的药物组合物及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872198A (zh) * | 2012-10-30 | 2013-01-16 | 陕西思尔生物科技有限公司 | 一种保肝胶囊及其制备方法 |
-
2013
- 2013-11-02 CN CN201310535588.6A patent/CN103519185A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872198A (zh) * | 2012-10-30 | 2013-01-16 | 陕西思尔生物科技有限公司 | 一种保肝胶囊及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 冷文慧等: "五味子果籽中木脂素与原花青素的RCO辅助优化提取的研究", 《食品科技》, vol. 37, no. 10, 20 October 2012 (2012-10-20) * |
| 王昌: "复方五味子护肝保健饮料的研制及其功能性评价的研究", 《中国优秀硕士学位论文全文数据库（电子期刊）（工程科技I辑）》, 30 November 2010 (2010-11-30) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784370A (zh) * | 2015-04-30 | 2015-07-22 | 陈大忠 | 一种能够清除自由基的抗氧化药物组合物及其制备方法 |
| CN104784371A (zh) * | 2015-04-30 | 2015-07-22 | 陈大忠 | 一种抗酒精性肝损伤的药物组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103330865A (zh) | 一种治疗非酒精性脂肪性肝炎的药物及制备方法 | |
| CN102743424A (zh) | 一种野菊花有效部位及其应用 | |
| CN103519185A (zh) | 用于防治化学性肝损伤的保健品 | |
| CN103230435A (zh) | 一种促进肝细胞再生的中药及其制备方法 | |
| CN103520148A (zh) | 对化学性肝损伤有辅助保护作用的制剂 | |
| CN101721455B (zh) | 一种饿蚂蟥提取物及其制备方法和应用 | |
| CN100457140C (zh) | 含有拉米夫定的药物组合物 | |
| CN103520191A (zh) | 五味子乙素制剂 | |
| CN103536614A (zh) | 含有大豆磷脂的组合物 | |
| CN103519186A (zh) | 对化学性肝损伤有辅助保护作用的保健食品 | |
| CN103519183A (zh) | 一种对化学性肝损伤有辅助保护作用的保健食品 | |
| CN103519184A (zh) | 含有甘草酸的保健品 | |
| CN104095940B (zh) | 一种治疗痛风的中药组合物 | |
| CN103040932B (zh) | 大叶糙苏提取物、提取方法及其应用 | |
| CN103536590A (zh) | 一种复方制剂 | |
| CN103550202A (zh) | 一种复方制剂 | |
| CN103520149A (zh) | 一种对化学性肝损伤有辅助保护作用的制剂 | |
| CN103550199A (zh) | 复方制剂 | |
| CN103550201A (zh) | 五味子制剂 | |
| CN1795901B (zh) | 一种清热解毒、利湿退黄的药物 | |
| CN103550236A (zh) | 复方牛磺酸制剂 | |
| CN103768450B (zh) | 一种中药组合物及其制备方法、制剂和应用 | |
| CN103550235A (zh) | 预防或治疗肝损伤的制剂 | |
| CN103550238A (zh) | 含有原花青素的组合物 | |
| CN103550234A (zh) | 复方齐墩果酸制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140122 |